Cargando…

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma

BACKGROUND: An important proportion of asthma patients remain uncontrolled despite using inhaled corticosteroids and long-acting beta-agonists. Clinical guidelines recommend, in these patients, using add-on long-acting muscarinic antagonists (triple therapy) to treatment with high doses of inhaled c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buendía, Jefferson Antonio, Patiño, Diana Guerrero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647470/ https://www.ncbi.nlm.nih.gov/pubmed/34865635 http://dx.doi.org/10.1186/s12890-021-01777-z

Ejemplares similares

Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

Cost-utility of vitamin D supplementation to prevent acute respiratory infections in children
por: Buendía, Jefferson Antonio, et al.
Publicado: (2023)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

Costs of Respiratory Syncytial Virus Hospitalizations in Colombia
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Cost-effectiveness of procalcitonin for detection of serious bacterial infections in children presenting with fever without source
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

Budget impact analysis of surfactant therapy for bronchiolitis in critically ill infants: the Colombian National Health System perspective
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

Disability-adjusted life years for acute bronchiolitis in infants in Colombia
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

Importance of respiratory syncytial virus as a predictor of hospital length of stay in bronchiolitis
por: Buendia, Jefferson Antonio, et al.
Publicado: (2022)

Impact of the updating of clinical guidelines for RSV bronchiolitis on the use of diagnostic testing and medications in tertiary hospitals in Colombia
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK
por: Kiff, Chris, et al.
Publicado: (2018)

Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence
por: Murphy, Kevin R, et al.
Publicado: (2009)

Budesonide inhalation suspension versus methylprednisolone for treatment of moderate bronchial asthma attacks
por: Yanagida, Noriyuki, et al.
Publicado: (2015)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
por: Kotoulas, Serafeim-Chrysovalantis, et al.
Publicado: (2023)

The cost-utility of early use of high-flow nasal cannula in bronchiolitis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

The Efficacy and Safety of First-Line Single-Inhaler Triple versus Dual Therapy in Controller-Naïve and Symptomatic Adults with Asthma: A Preliminary Retrospective Cohort Study
por: Fujiki, Rei, et al.
Publicado: (2023)

The Extra Cost Due to Non-Adherence to Inhaled Treatments in Adolescents with Mild-to-Moderate Persistent Asthma
por: Dal Negro, Roberto Walter, et al.
Publicado: (2023)

Overuse of reliever inhalers and associated healthcare utilization of asthma patients
por: Hadad, Ronit, et al.
Publicado: (2020)

Effect of High Dose Inhaled Glucocorticoids on Quality of Life in Patients with Moderate to Severe Asthma
por: Choi, Jae-Sung, et al.
Publicado: (2005)

Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma
por: Pinto, Charleston Ribeiro, et al.
Publicado: (2013)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain
por: Barrecheguren, Miriam, et al.
Publicado: (2022)

Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications
por: Agusti, Alvar, et al.
Publicado: (2021)

When single-inhaler triple therapy is a preferred option in asthma management?
por: Al-Moamary, Mohamed S., et al.
Publicado: (2022)

Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
por: Resta, Emanuela, et al.
Publicado: (2022)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
por: de Nigris, Enrico, et al.
Publicado: (2022)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a2rqfrk1fi4ogrqnm9075l362l